INDSWFTLABBSEIND SWIFT LABORATORIES LTMediumNeutral
Announced Thu, 20 Aug · 17:55 IST

Q1 FY27 call: revenue up 21%, EBITDA margin expands to 17.9%

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹333.02
prior close
₹335.17
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.8-0.9-1.2
Up moveDown movePending
AI summary

Ind-Swift Labs Q1 FY27 revenue grew 21% YoY to Rs 186.08 cr. Operating EBITDA jumped 2.85x to Rs 33.32 cr with margin expanding 1258 bps to 17.91%. PAT (ex-exceptional) rose 2.04x to Rs 24.68 cr. CDMO tie-ups with Viatris, Manx UK, and Arrotex Australia commercialized, expected to add Rs 200-220 cr in FY27. Export share rose to 57.2% of sales from 48%. Management guides 18% sustainable EBITDA margin, possibly 21-22%, Rs 900 cr FY27 revenue, Rs 1,200 cr by FY29, and Rs 1,500 cr revenue with Rs 200 cr plus PAT by FY30. Capex of Rs 250 cr planned over 2.5 years.

Likely market impact

Strong margin expansion and CDMO ramp-up signal improving earnings quality; multiyear revenue targets point to sustained growth ahead.